WP
RIGL icon

Woodline Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Woodline Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.35M Hold
50,000
– – 0.01% 843
2025
Q4 		$2.14M Buy
+50,000
New +$1.88M 0.01% 761
2022
Q3 		– Sell
-86,131
Closed -$973K – 811
2022
Q2 		$973K Buy
86,131
+3,765
+5% +$75.6K 0.02% 520
2022
Q1 		$2.46M Buy
+82,366
New +$2.23M 0.04% 351

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners's RIGL Position: Q1 2026 in Review

Woodline Partners held its Rigel Pharmaceuticals (RIGL) position steady in Q1 2026 at 50,000 shares worth $1.35M. The position accounts for 0.01% of the portfolio, ranked #843.

Woodline Partners first reported a position in RIGL in Q1 2022 and has held it in 4 quarters since. The position peaked at $2.46M in Q1 2022. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Woodline Partners held 50,000 shares of Rigel Pharmaceuticals worth $1.35M as of Q1 2026.
  • Woodline Partners left its Rigel Pharmaceuticals share count unchanged in Q1 2026.
  • Rigel Pharmaceuticals made up 0.01% of Woodline Partners's portfolio in Q1 2026, its #843 holding.
  • Woodline Partners first reported a position in Rigel Pharmaceuticals in Q1 2022 and has held it in 4 quarters since.
  • Woodline Partners's Rigel Pharmaceuticals position peaked at $2.46M in Q1 2022.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.